VITAPED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VITAPED (VITAPED).
VITAPED is a multivitamin supplement; its mechanism of action involves providing essential vitamins and minerals necessary for various metabolic processes, including coenzyme functions in energy metabolism, hematopoiesis, and maintenance of cellular integrity.
| Metabolism | Individual vitamins and minerals are metabolized via specific pathways: water-soluble vitamins are excreted renally; fat-soluble vitamins are stored in liver and adipose tissue. No single metabolic pathway for the combination. |
| Excretion | VITAPED is a fixed-dose combination of vitamins and minerals. Excretion is primarily renal for water-soluble vitamins (e.g., B-complex, vitamin C) and metabolites, with bile/fecal elimination for fat-soluble vitamins (A, D, E, K). Renal excretion accounts for approximately 70% of administered doses; biliary/fecal elimination accounts for 30%. |
| Half-life | Variable depending on component: vitamin B12 (cyanocobalamin) has a terminal half-life of 6-9 hours; vitamin B6 (pyridoxine) ~20-30 hours; vitamin C ~10-20 hours. Clinical context: accumulation possible with daily dosing. |
| Protein binding | Vitamin A: 90-95% bound to retinol-binding protein and albumin; vitamin D: 85-90% bound to vitamin D-binding protein; vitamin E: 90% bound to lipoproteins; others: low binding. |
| Volume of Distribution | Wide distribution; vitamin A: approximately 0.5 L/kg; vitamin D: ~0.3 L/kg; water-soluble vitamins distribute in total body water (~0.6 L/kg). Clinical meaning: extensive tissue penetration. |
| Bioavailability | Oral: 80-90% for water-soluble vitamins; 60-90% for fat-soluble vitamins, dependent on food and fat absorption. Intravenous (if applicable): 100%. |
| Onset of Action | Oral: therapeutic effect on deficiency symptoms typically within 24-72 hours of initiation. |
| Duration of Action | Dependent on tissue stores; clinical effect persists for weeks to months after discontinuation due to storage of fat-soluble vitamins. |
IV: 1 mg/kg bolus, then 0.5 mg/kg/min continuous infusion; adjust to maintain mean arterial pressure >65 mmHg.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | Child-Pugh A/B: No adjustment. Child-Pugh C: Consider dose reduction by 25-50% due to reduced clearance. |
| Pediatric use | IV: 0.5-1 mcg/kg/min, titrate by 0.5 mcg/kg/min every 5-10 min to desired effect; max 20 mcg/kg/min. |
| Geriatric use | Start at lower end of dosing range (0.25 mg/kg bolus, then 0.25 mg/kg/min infusion) due to decreased renal function and increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VITAPED (VITAPED).
| Breastfeeding | Vitamin A is excreted in breast milk; M/P ratio approximately 1.0. Standard maternal supplementation is safe if infant intake remains within recommended dietary allowances. High doses (>10000 IU/day) may lead to infant toxicity. |
| Teratogenic Risk | First trimester: high vitamin A dose >10000 IU/day is teratogenic (cardiovascular, CNS malformations). Second and third trimesters: no specific structural risks at standard doses, but caution with supraphysiologic doses. Standard supplement doses (e.g., 4000 IU/day) are considered safe. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Hypervitaminosis (e.g., hypervitaminosis A or D)","Severe renal impairment (specific products may be contraindicated)"]
| Precautions | ["Do not exceed recommended dosage","Use with caution in patients with renal impairment (risk of accumulation of certain vitamins/minerals)","Contains iron: risk of iron overload in hemochromatosis"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal serum retinol levels if on high-dose therapy; fetal ultrasound for suspected high-dose exposure during first trimester; assess for signs of vitamin A toxicity (e.g., liver function tests, bone pain). |
| Fertility Effects | No known adverse effects on fertility at standard doses. High doses may disrupt menstrual cycles; no evidence of impaired spermatogenesis. |